Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last SFr.99.95 CHF
Change Today -0.05 / -0.05%
Volume 45.6K
BSLN On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
As of 11:43 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

basilea pharmaceutica-reg (BSLN) Snapshot

Open
SFr.100.90
Previous Close
SFr.100.00
Day High
SFr.101.50
Day Low
SFr.99.20
52 Week High
05/26/15 - SFr.139.30
52 Week Low
10/16/14 - SFr.79.75
Market Cap
1.1B
Average Volume 10 Days
78.3K
EPS TTM
SFr.-5.30
Shares Outstanding
10.8M
EX-Date
04/11/13
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BASILEA PHARMACEUTICA-REG (BSLN)

Related News

No related news articles were found.

basilea pharmaceutica-reg (BSLN) Related Businessweek News

No Related Businessweek News Found

basilea pharmaceutica-reg (BSLN) Details

Basilea Pharmaceutica AG, together with its subsidiaries, operates as an integrated biopharmaceutical company in Switzerland, China, and internationally. The company focuses on the discovery, development, and commercialization of pharmaceutical products in the therapeutic areas of bacterial and fungal infections, and oncology. It offers Toctino, a therapy for the treatment of adult patients with severe chronic hand eczema, who do not respond to potent topical corticosteroids; and Ceftobiprole, a bactericidal antibiotic for the treatment of hospital and community-acquired pneumonia under the brand name of Zevtera. The company is also developing Isavuconazole, an antifungal drug for the treatment of invasive fungal infections, which is under regulatory review by the European Medicines Agency and the U.S. Food and Drug Administration; BAL30072, a monosulfactam antibiotic with bactericidal activity against multidrug-resistant gram-negative bacteria under Phase I clinical development; and BAL101553, a small-molecule anti-cancer drug in Phase IIa clinical development. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

230 Employees
Last Reported Date: 02/12/15
Founded in 2000

basilea pharmaceutica-reg (BSLN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.1.0M
Compensation as of Fiscal Year 2014.

basilea pharmaceutica-reg (BSLN) Key Developments

Basilea Pharmaceutica Ltd. Announces Executive Changes, Effective from February 1, 2016

Basilea Pharmaceutica Ltd. announced that Dr. Ingrid Heinze-Krauss will retire after 15 years with the company. Basilea named Dr. Günter Ditzinger, currently Head of Pharmaceutics, to succeed Dr. Heinze-Krauss in the role of Chief Technology Officer and as a member of the management committee effective February 1, 2016. Dr. Ditzinger joined Basilea in 2002 as CMC Project Leader & Pharmaceutical Development Manager. He was promoted in 2009 to Head of Pharmaceutics in which position he led the pharmaceutical development and manufacturing group and acted as Dr. Heinze-Krauss' deputy. Prior to joining Basilea, he held various positions with increasing responsibility at Hoechst Marion Roussel in Frankfurt, Germany and at Novartis Pharma AG in Basel, Switzerland.

Basilea Pharmaceutica AG Announces Unaudited Consolidated Earnings Results for the First Half Ended June 30, 2015; Provides Earnings Guidance for the Year 2015

Basilea Pharmaceutica AG announced unaudited consolidated earnings results for the first half ended June 30, 2015. For the period, the company's total revenue was CHF 25.0 million compared with CHF 20.3 million a year ago. Operating loss was CHF 30.0 million compared with CHF 19.5 million a year ago. This change is mainly due to higher operating expenses related to commercial activities for ceftobiprole and pre-launch activities for isavuconazole. Net loss was CHF 30.1 million or CHF 3.0 per basic and diluted share compared with CHF 19.4 million or CHF 1.97 per basic and diluted share a year ago. Net cash used for operating activities was CHF 19.3 million compared with CHF 44.9 million a year ago. The decrease is mainly due to the milestone payment of CHF 30.0 million received from Astellas in the first half of 2015 upon approval of isavuconazole in the U.S. Combined cash and short-term investments amounted to CHF 218.4 million as of June 30, 2015, compared to CHF 226.1 million as of December 31, 2014. The company's operating loss in 2015 is estimated at approximately CHF 4 million-CHF 5 million on average per month.

Basilea's ceftobiprole Receives QIDP Designation from U.S. FDA for the Treatment of Lung and Skin Infections

Basilea Pharmaceutica Ltd. announced that the U.S. Food and Drug Administration designated its investigational drug ceftobiprole as a Qualified Infectious Disease Product. The designation relates to the potential use of the drug in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Qualified Infectious Disease Product (QIDP) status, granted under the Generating Antibiotic Incentives Now (GAIN) Act, provides certain incentives for the development of antibiotics, such as priority review if the product is submitted for approval in the United States, and a five-year extension of certain periods of market exclusivity that may be applicable should it be approved.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSLN:SW SFr.99.95 CHF -0.05

BSLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BSLN.
View Industry Companies
 

Industry Analysis

BSLN

Industry Average

Valuation BSLN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.3x
Price/Book 23.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BASILEA PHARMACEUTICA-REG, please visit www.basileapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.